Targeting MORC2 activates transposable element-mediated viral mimicry and potentiates immune checkpoint blockade in triple-negative breast cancer
Fang-Lin Zhang, Shao-Ying Yang, Yin-Ling Zhang, Qian Zhao, Wen-Xiao Yang, Lisa Andriani, Jia-Yang Cai, Min-Ying Huang, Xin Hu, Zhi-Min Shao, A-Yong Cao, Da-Qiang Li · 2026
Read Targeting MORC2 activates transposable element-mediated viral mimicry and potentiates immune checkpoint blockade in triple-negative breast cancer by Fang-Lin Zhang, Shao-Ying Yang, Yin-Ling Zhang, Qian Zhao, Wen-Xiao Yang, Lisa Andriani, Jia-Yang Cai, Min-Ying Huang, Xin Hu, Zhi-Min Shao, A-Yong Cao, Da-Qiang Li (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13420440.txt.
Description
Fang-Lin Zhang and colleagues identified a chromatin remodeler, MORC2, in 2026 that shields triple-negative breast cancer from immunotherapy. Checkpoint drugs often fail in this aggressive subtype, and the team found MORC2 high in tumors with cold immune surroundings and poor checkpoint response.
Removing MORC2 slowed tumors only when immunity was intact, boosting killer T cells, while MORC2 and its partner SETDB1 silenced jumping-gene elements that would otherwise trip viral alarms. Antisense drugs against MORC2 plus anti-PD-1 therapy shrank mouse tumors together, nominating MORC2 as a new epigenetic immune checkpoint for combination trials.
Catalog record
| CREATOR | Fang-Lin Zhang, Shao-Ying Yang, Yin-Ling Zhang, Qian Zhao, Wen-Xiao Yang, Lisa Andriani, Jia-Yang Cai, Min-Ying Huang, Xin Hu, Zhi-Min Shao, A-Yong Cao, Da-Qiang Li |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 87 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |